Printer Friendly

CELEX LICENSEE ESTABLISHED; COMMERCIAL PRODUCTION OF TAXOL IN 1994

 VANCOUVER, British Columbia, Nov. 15 /PRNewswire/ -- Pursuant to the company's news release dated Sept. 10, 1993, Multiplex has, subject to Vancouver Stock Exchange (VSE) approval, acquired a majority interest in Celex Laboratories (NB) Inc., a company involved in research and development of agrobacterium technologies for the production of Taxol and other plant-derived pharmaceutical compounds and biological plant- related technology.
 Celex Laboratories (NB) Inc. announced appointment of a licensee which will utilize Celex Laboratories' patented process to produce Taxol and other plant-derived pharmaceutical compounds from genetically cloning root cultures.
 Naturally occurring taxus seeds from the Pacific Northwest are grown into seedlings, which are altered by infecting them with specific strains of certain bacteria. The roots react to the infection by producing "hairy" roots which grow in culture much more rapidly than normal roots and which can be cloned repeatedly. The roots double in size in half a day and after three weeks are developed enough for the next stage of Celex's process; extraction of taxanes for the manufacturing of Taxol which is currently used as an agent to treat ovarian cancer. By using cultured roots for taxane extraction, instead of the conventional yew tree bark and needles, many expensive steps are eliminated from the extraction and purification process and the need to destroy old growth Pacific yew trees is eliminated.
 Using this technology, Celex will have a tremendous cost advantage over other producers of the chemical. Celex is scaling up its root production and taxane extraction method, again using its own proprietary process, and expects to be in full production within the next 12 months. Two manufacturing facilities will be established to meet the initial demand. Engineering and design of special equipment to meet the unique manufacturing requirements dictated by Celex's patented cloning process are now underway. The major U.S. forestry company, Weyerhauser, is collaborating with Celex in technology development and a multinational pharmaceutical company is discussing the purchase of Celex's chemicals as the starting materials for its anti-cancer agent.
 Taxol is generally regarded as the most promising anti-tumor chemical discovered in the last 15 years. Taxol is FDA-approved for use in fighting ovarian cancer. It is also presently under FDA consideration for use in treating breast and lung cancers.
 Multiplex Technologies Inc. is a diversified company, developing leading technologies for commercialization in biomedicine, water purification, waste water and air pollution control and abatement.
 -0- 11/15/93
 /NOTE TO EDITORS: The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release./
 /CONTACT: Ron Davis of Multiplex Technologies, 800-661-2388/
 (MPX.)


CO: Multiplex Technologies Inc.; Celex Laboratories (NB), Inc. ST: British Columbia IN: MTC SU: TNM LIC

MP -- NY003 -- 4201 11/15/93 08:32 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1993
Words:455
Previous Article:EDS AND FASTECH TEAM TO PROVIDE INNOVATIVE SOLUTIONS FOR MANUFACTURING CUSTOMERS
Next Article:IEEE AGREES ON A FOUNDATION MEDIA ACCESS CONTROL APPROACH TO WIRELESS LOCAL AREA NETWORKS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters